IL17A and inflammatory bowel disease: The low incidence rate reported in the current meta-analysis is consistent with a rate of 2.4 per 1,000 patient-years, as reported in a previous meta-analysis that investigated the risk of IBD associated with interleukin-17A inhibitors in RCTs (40).